COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01223209
Recruitment Status : Completed
First Posted : October 18, 2010
Last Update Posted : January 11, 2012
Kael-GemVax Co., Ltd.
Information provided by (Responsible Party):
Lytix Biopharma AS

Brief Summary:

This study involves testing of the medicine LTX-315 combined with a cancer vaccine (GV1001). This will be tested in patients that have had surgery with curative intent for malignant tumour.

GV1001 is a peptide vaccine in development to treat cancer. An adjuvant, is required to start the immune response in the body to have effect of GV-1001.

LTX-315, also a peptide, in development for cancer treatment. In this study, the investigators wish to find out whether LTX-315 can make GV1001 more effective at stimulating the immune system.

Condition or disease Intervention/treatment Phase
Carcinoma Drug: LTX-315 Phase 1

Detailed Description:

This clinical study has two main aims which are:

  • To measure the immunological effects of LTX-315 in combination with GV1001
  • Find out about the side effects of the combination of the two drugs This is an open label, single centre study assessing immunological effects and safety of LTX-315 given as an adjunct to GV1001. The LTX-315 dose will escalate while the GV1001 dose will be fixed.

LTX-315 and GV1001 will be given as intradermal injections on days 1, 8, 15, 22 and 36.

Investigational treatment: LTX-315 (0.10 mL) with escalating concentrations will be injected intradermally, followed, 1-2 hours later, by intradermal injection of 0.56 mg GV1001 (0.20 mL, 2.8 mg/mL) in the same site, in one arm.

DTH-test control: 0.10 mg GV1001 (0.10 mL) will be injected intradermally in the contralateral arm without LTX-315, as a DTH skin reactivity test control.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: A Phase I, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma
Study Start Date : August 2010
Actual Primary Completion Date : December 2011
Actual Study Completion Date : January 2012

Arm Intervention/treatment
Experimental: LTX-315
The dose range of 0,25-2.0 mg/ML LTX-315 will be used. In combination with a fixed dose of GV-1001.
Drug: LTX-315
0.25-2.0 mg/ML, maximum 5 injections during 36 days.
Other Name: GV-1001

Primary Outcome Measures :
  1. Immunological effects of LTX-315 in combination with GV1001 as measured by DTH skin test reaction and T-cell function in peripheral blood. [ Time Frame: 5 injections, treatment period 36 days ]
    Patients will return to the site 24 to 48 hours after the LTX-315 and GV1001 injections for DTH assessment and in week 10 for an end of study assessment.

Secondary Outcome Measures :
  1. To evaluate the safety profile of LTX-315 in combination with GV1001 study [ Time Frame: 5 injections, treatment period 36 days ]
    Assessment of adverse events and abnormal laboratory values recorded during the

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Curative surgery for carcinoma performed at least three months prior to treatment start
  • Age ≥18 years
  • ECOG Performance status (PS): 0
  • Life expectancy: at least 3 months
  • Laboratory requirements:

    • White Blood Count (WBC) ≥ 3 x 109/L
    • Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
    • Platelet count ≥ 100 x 109/L
    • Haemoglobin ≥ 10.0 g/dL
    • Total bilirubin level ≤ 1.5 ULN
    • AST and ALT ≤ 2.5 x ULN
    • Creatinine ≥ 1.5 ULN
    • Albumin > 30 g/L
  • No expectation of anti-cancer therapy or immunotherapy during the trial period, hormone therapy given as adjunctive or contraceptive therapy is permitted
  • Must be willing to practice acceptable barrier methods of birth control to prevent pregnancy
  • The patient is willing and able to comply with the protocol and agrees to return to the hospital for follow-up visits and examination
  • The patient has been fully informed about the study and has signed the informed consent form

Exclusion Criteria:

  • Has received an investigational drug within 4 weeks prior to study drug administration, or is scheduled to receive one during the treatment or the post-treatment period
  • Has received immunotherapy or been vaccinated within 12 weeks prior to study drug administration or has not recovered from adverse events due to such agents
  • Has received external radiotherapy or cytotoxic chemotherapy within the last 4 weeks prior to study drug administration, or has not recovered from adverse events (< Grade 1) due to agents administered more than 4 weeks earlier
  • Has received imiquimod within 12 weeks prior to study drug administration or has not recovered from associated adverse events
  • Is currently on any agent with a known effect on the immune system
  • Has any other serious illness or medical condition such as but not limited to:

    • Any uncontrolled infection or infection requiring antibiotics
    • Uncontrolled cardiac failure Classification III or IV (New York Heart Association)
    • Uncontrolled systemic and gastro-intestinal inflammatory conditions
    • Bone marrow dysplasia
    • History of auto-immune disease
    • History of adverse reaction to vaccines
  • Known history of positive tests for HIV/AIDS, hepatitis B or C
  • Is pregnant or breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01223209

Layout table for location information
University Hospital North-Norway
Tromsø, Norway, 9038
Sponsors and Collaborators
Lytix Biopharma AS
Kael-GemVax Co., Ltd.
Layout table for investigator information
Principal Investigator: Tone Nordøy, MD, PhD Tromsø University Hospital
Layout table for additonal information
Responsible Party: Lytix Biopharma AS Identifier: NCT01223209    
Other Study ID Numbers: C09-315-02
First Posted: October 18, 2010    Key Record Dates
Last Update Posted: January 11, 2012
Last Verified: January 2012
Keywords provided by Lytix Biopharma AS:
Curative surgery
Curative surgery for carcinoma at least three months and not more than 5 years prior to treatment start
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type